Alzheimer’s Drug Sales to Top $7 Billion, Eisai Says (Correct)

Eisai Co.’s revenue from its new Alzheimer’s disease drug Leqembi is forecast to reach ¥1 trillion ($7.3 billion) in fiscal 2030 as its use expands, the Japanese drugmaker said.

The company will first pursue broad access in the US, Japan and Europe, followed by China and the rest of Asia, it said in materials prepared for a media briefing being held Thursday. Wider availability of blood-based biomarkers to detect people who may benefit from it will further boost use, Eisai said.

“I’m expecting Leqembi to take an overwhelming market share” because of what the drug targets, Chief Executive Officer ...